To evaluate the availability and quality of evidence on the achievement of pharmacodynamic targets and clinical outcomes when adjusting beta-lactam dosages in critically ill patients with acute kidney injury (AKI), emphasizing the need for optimized treatment outcomes.
Key Findings:
High incidence of AKI in critically ill patients complicates antibiotic dosing, highlighting the need for careful management.
Beta-lactam antibiotics are commonly underdosed due to reliance on unreliable eGFR in this population, which may lead to treatment failures.
Initial dose reductions may not be necessary in cases of transient AKI, as many cases resolve quickly, suggesting a need for reevaluation of dosing strategies.
Interpretation:
The review highlights the need for more robust evidence on beta-lactam dosing in AKI to optimize treatment outcomes, suggesting that dose adjustments may be reconsidered based on the dynamic nature of renal function in critically ill patients, particularly in the first 48 hours.
Limitations:
Limited high-quality evidence specifically addressing beta-lactam dosing in AKI, which may affect the reliability of recommendations.
Most existing reviews are based on expert opinion rather than systematic data, limiting the strength of conclusions drawn.
Conclusion:
Further research is needed to clarify the optimal dosing strategies for beta-lactam antibiotics in critically ill patients with AKI, particularly in the first 48 hours of treatment, focusing on specific patient populations and renal function trajectories.
